Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Effects of validating communication on recall during a pain-task in healthy participants.

Carstens JKP, Boersma K, Schrooten MGS, Linton SJ.

Scand J Pain. 2017 Aug 12;17:118-125. doi: 10.1016/j.sjpain.2017.07.003. [Epub ahead of print]

PMID:
28850364
2.

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer.

Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R.

Nat Commun. 2017 Apr 27;8:15095. doi: 10.1038/ncomms15095.

3.

Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.

Tampe B, Steinle U, Tampe D, Carstens JL, Korsten P, Zeisberg EM, Müller GA, Kalluri R, Zeisberg M.

Kidney Int. 2017 Jan;91(1):157-176. doi: 10.1016/j.kint.2016.07.042. Epub 2016 Sep 28.

PMID:
27692563
4.

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2015 Dec 14;28(6):831-833. doi: 10.1016/j.ccell.2015.11.002. Epub 2015 Dec 14. No abstract available.

5.

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R.

Nature. 2015 Nov 26;527(7579):525-530. doi: 10.1038/nature16064. Epub 2015 Nov 11.

6.

Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.

Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R.

Nat Med. 2015 Sep;21(9):998-1009. doi: 10.1038/nm.3902. Epub 2015 Aug 3.

7.

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.

J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

8.

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2014 Jun 16;25(6):719-34. doi: 10.1016/j.ccr.2014.04.005. Epub 2014 May 22. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831-3.

9.

Microenvironment-dependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch.

Carstens JL, Lovisa S, Kalluri R.

J Clin Invest. 2014 Apr;124(4):1458-60. doi: 10.1172/JCI75239. Epub 2014 Mar 18.

10.

FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM.

Cancer Res. 2014 Jan 15;74(2):609-20. doi: 10.1158/0008-5472.CAN-13-1093. Epub 2013 Dec 4.

11.

When the wind goes out of the sail - declining recovery expectations in the first weeks of back pain.

Carstens JK, Shaw WS, Boersma K, Reme SE, Pransky G, Linton SJ.

Eur J Pain. 2014 Feb;18(2):269-78. doi: 10.1002/j.1532-2149.2013.00357.x. Epub 2013 Jul 3.

PMID:
23824730
12.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

13.

The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients.

Ozbay LA, Møller N, Juhl C, Bjerre M, Carstens J, Rungby J, Jørgensen KA.

Diabet Med. 2012 Dec;29(12):e440-4. doi: 10.1111/dme.12028.

PMID:
23003106
14.

Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis.

Shahi P, Park D, Pond AC, Seethammagari M, Chiou SH, Cho K, Carstens JL, Decker WK, McCrea PD, Ittmann MM, Rosen JM, Spencer DM.

PLoS One. 2012;7(1):e30814. doi: 10.1371/journal.pone.0030814. Epub 2012 Jan 27.

15.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W.

N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. Erratum in: N Engl J Med. 2012 Jul 12;367(2):189.

16.

Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.

Øzbay LA, Møller N, Juhl C, Bjerre M, Carstens J, Rungby J, Jørgensen KA.

Br J Clin Pharmacol. 2012 Apr;73(4):536-45. doi: 10.1111/j.1365-2125.2011.04118.x.

17.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

18.

Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.

Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J.

Br J Pharmacol. 2011 Jan;162(1):136-46. doi: 10.1111/j.1476-5381.2010.01018.x.

19.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators.

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
20.

Transcriptional profiles in urine during acute rejection, bacteriuria, CMV infection and stable graft function after renal transplantation.

Øzbay A, Tørring C, Olsen R, Carstens J.

Scand J Immunol. 2009 Apr;69(4):357-65. doi: 10.1111/j.1365-3083.2009.02226.x.

Supplemental Content

Loading ...
Support Center